S., Min, E., Huang, J., Chu, H
that it reduces cardiovascular mortality (outcomes trial ongoing) What readers should know: Foundayo is a real, FDA-approved treatment option, but it produces less average weight loss than injectable alternatives, and cost and insurance coverage vary significantly Who Faces the Greatest Risk or May Benefit Most
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized dose-ranging study
Additionally, the medication has been shown to improve other aspects of metabolic health, such as controlling blood sugar and reducing inflammation
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial